15 February 2024
15 February 2024
A panel at the 2024 SCOPE Summit shared their experiences of setting up and running clinical trials that are more inclusive of the LGBTQIA+ community.
The studies are sponsored by Erasca while Novartis will provide trametinib at no cost for the trial.
The trial is expected to complete enrolment ahead of schedule in Q1 2024.
The DURIPANC study is aimed at assessing the safety and efficacy of the combination regimen of Ampligen and Imfinzi.
Measuring the overall response rate according to RECIST 1.1 criteria is the trial’s primary goal.
Initially, the trial will commence at study sites in Poland and Italy, with plans to extend to up to 80 sites.
RBI-4000 induced neutralising antibody titres at levels that exceeded the WHO’s defined surrogate level of protection for rabies virus.
The company’s implant will be tested in around 245 patients with later stage patellofemoral cartilage degeneration.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
